Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vitamin D Deficiency in Patients With Hypertension

This study has been terminated.
(Administrative/Sponsor Business Decision)
Information provided by (Responsible Party):
William B. White, University of Connecticut Health Center Identifier:
First received: September 10, 2009
Last updated: July 23, 2012
Last verified: July 2012
This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood pressure who have low levels of vitamin D in their blood. The study will compare the effects of vitamin D or aliskiren alone and in combination on 24-hour blood pressure and biochemical parameters.

Condition Intervention Phase
Vitamin D Deficiency
Drug: aliskiren (Tekturna)
Dietary Supplement: cholecalciferol (Vitamin D3)
Dietary Supplement: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension

Resource links provided by NLM:

Further study details as provided by UConn Health:

Primary Outcome Measures:
  • Change in the baseline blood pressure measurement in 24-hour mean diastolic blood pressure. [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Change from baseline blood pressure measurement in 24-hour systolic BP, changes in awake and sleep systolic and diastolic BP, and changes from baseline in clinic systolic and diastolic BP. [ Time Frame: 6 weeks ]

Enrollment: 40
Study Start Date: August 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Phase 1
Two weeks of single-blind placebo, then randomized in a double-blind fashion to aliskiren 150 mg to 300 mg or Vitamin D3 (3000 I.U.) once daily for 6 weeks.
Drug: aliskiren (Tekturna)
150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
Other Name: Tekturna
Dietary Supplement: cholecalciferol (Vitamin D3)
3,000 I.U. once daily for 6 weeks.
Other Name: Vitamin D3
Dietary Supplement: Placebo
Active Comparator: Phase 2
Aliskiren 150-300 mg orally once daily and Vitamin D3 3000 IU in combination once daily for 6 weeks.
Drug: aliskiren (Tekturna)
150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
Other Name: Tekturna
Dietary Supplement: cholecalciferol (Vitamin D3)
3,000 I.U. once daily for 6 weeks.
Other Name: Vitamin D3

Detailed Description:
This study will assess whether aliskiren will lower clinic blood pressure and 24-hour blood pressure in patients with hypertension and vitamin D deficiency. Additionally, this study will further explore the potential additional effects of adding vitamin D to aliskiren in this patient population.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women over 21 years of age with a history of Stage 1 or 2 hypertension (defined as a seated diastolic BP ≥ 90 mmHg and < 110 mmHg in the untreated state).
  • Patients under treatment for hypertension must be willing and able to discontinue any previous antihypertensive medications for the duration of the study.
  • 25-hydroxyvitamin D levels < 30 ng/ml and > 12 ng/ml.
  • Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial, must have a negative serum pregnancy test at screening, and must have a negative urine pregnancy test within 7 days before initiating aliskiren therapy.

Exclusion Criteria:

  • Vitamin D levels < 12 ng/ml
  • Known hypersensitivity or allergy to aliskiren
  • Clinic blood pressure > 180/110 mmHg
  • Known forms of secondary hypertension
  • Chronic atrial fibrillation
  • Uncontrolled or unstable cardiovascular diseases
  • Shift or night workers
  • Mid-arm circumference > 42 cm in diameter
  • Current or recent (<1 year) alcohol or drug abuse
  • Pregnant or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00974922

United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
Principal Investigator: William B White, M.D. Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center
  More Information

Responsible Party: William B. White, Professor of Medicine, University of Connecticut Health Center Identifier: NCT00974922     History of Changes
Other Study ID Numbers: 091661
Study First Received: September 10, 2009
Last Updated: July 23, 2012

Keywords provided by UConn Health:
Vitamin D

Additional relevant MeSH terms:
Vitamin D Deficiency
Vascular Diseases
Cardiovascular Diseases
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on April 27, 2017